𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Considerations on131I-metaiodobenzylguanidine therapy of six children with neuroblastoma

✍ Scribed by Sanguineti, Michele

Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
289 KB
Volume
15
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Six children affected by neuroblastoma at stages III and IV were treated with high-specific-activity 131I-metaiodobenzylguanidine (MIBG). After 131I-MIBG treatment three patients died at 12, 10, and 12 weeks, respectively; the other three were still living at 21, 16, and 24 weeks, respectively. Although the assumptions for this therapy were propitious, the results obtained do not correspond to those expected. It is supposed that large tumor volume and previous chemotherapy and/or radiotherapy may impair the effectiveness of 131I-MIBG therapy. Consequently, 131I-MIBG therapy is recommended even if the spread of disease is not proved-only, however, when the tumor is small.

πŸ“œ SIMILAR VOLUMES

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine
✍ Troncone, L. ;Riccardi, R. ;Montemaggi, P. ;Rufini, V. ;Lasorella, A. ;Mastrange πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 345 KB

Seven patients with neuroblastoma (six children and one adult) were treated with therapeutic doses of high specific activity 131I-metaiodobenzylguanidine (131I-MIBG). Six patients were in stage IV and unresponsive to conventional treatment. One patient, in stage III, was treated at diagnosis, an app

Second malignancies in children with neu
Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine
✍ Alberto Garaventa; Claudio Gambini; Giampiero Villavecchia; Andrea Di Cataldo; L πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 127 KB

## Abstract ## BACKGROUND ^131^I‐metaiodobenzylguanidine (^131^I‐MIBG) is selectively taken up by cells of neural crest origin, allowing targeted radiotherapy of tumors such as neuroblastoma (NB) and pheochromocytoma. Radiotherapy may provide additional benefits in the treatment of NB, with modera

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: Experience of the MΓΌnster/Kassel group
✍ Fischer, M. ;Wehinger, H. ;Kraus, C. ;Ritter, J. ;SchrΓΆter, W. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 205 KB

I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Becaus

Treatment of neuroblastoma with131I-meta
Treatment of neuroblastoma with131I-metaiodobenzylguanidine: The experience of an Italian study group
✍ Bestagno, M. ;Guerra, P. ;Puricelli, G. P. ;Colombo, L. ;Calculli, G. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 182 KB

Eight patients affected by neuroblastoma were treated with 18 courses of 131I-meta-iodobenzylguanidine (MIBG). They all had been judged as "nonresponders" to conventional treatments. Six had stage IV disease: of these, five, with massive marrow involvement, had poor results, mainly because of marrow

Improved radiation protection of the thy
Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma
✍ Hanneke M. van Santen; Jan de Kraker; Berthe L. F. van Eck; Jan J. M. de Vijlder πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 101 KB

## Abstract ## BACKGROUND During radiolabeled metaiodobenzylguanidine (MIBG) administration in children with neuroblastoma, the thyroid is protected from ^123/131^I uptake by potassium iodide. Despite this protection, up to 64% of patients develop thyroid dysfunction. The authors introduce a new m